Community

Advertising Opportunities

 Biotechnology Europe Programs

 Resources

Biotechnology Europe Community

Feedback

Contact

Biotechnology Europe Advantages

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

 

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe

Terms of Business

Imprint

Privacy Policy

FAQ

Subscribe Newsletter

 

Pfizer and Merck News

   

 

 

   
     

   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
   
   
   
   
   
   
   
   
   
   
   

post your news I subscribe newsletter I contact us

 
 
     

 

 

Pfizer, Merck cutting jobs following mergers

12 January 2010

 

Fresh off major acquisitions of rivals, drugmakers Pfizer Inc. and Merck & Co. are each planning to eliminate hundreds of jobs.

 

According to reports, Pfizer will eliminate nearly 1,200 jobs, including 680 in Pennsylvania, 400 in New Jersey, and 116 in Rockland County, N.Y. Meanwhile Merck will cut 500 jobs in New Jersey.

 

Pfizer, which is based in New York, bought vaccine maker Wyeth for $68 billion in October, while Merck paid $41.1 billion for Schering-Plough Corp. in November. Both are planning to eliminate thousands more jobs.


 

A Pfizer spokesman says the cuts were disclosed when the merger closed. A representative for Merck of Whitehouse Station, N.J., didn't immediately respond to requests for comment.

 

Combined, Pfizer and Wyeth plan to cut about 20,000 jobs, or 15 percent of their combined staff. In November, Pfizer said it would eliminate about 2,000 scientist and laboratory technician jobs. Merck said it planned to eliminate about 16,000 of the 106,000 staff positions it had after the Schering-Plough deal was complete.

 

 

 

   

 

 

More Pfizer News I add this page to your favorites

 
Pfizer taking more targeted approach to R&D
 
Lipitor Significantly Reduced hsCRP Levels in Patients with Stable Coronary Artery Disease, According to New Study
Pfizer expanding in Cambridge
Pfizer Inc.  to Buy Wyeth for $68 Billion; Slashes More Than 8,000 Jobs
 
   

 
 
 
Google
 
 
 
 I back I top I  

 

 

                                                                

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved